Heart failure & cardiomyopathies
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis
Pooled resultResult — go to the resultHazard ratio 0.85 95% CI 0.80–0.90Authors' conclusion
Treatment with digitalis glycosides was associated with a lower risk of the composite of cardiovascular death or first worsening HF event in patients with HFmrEF or HFrEF, mainly through a lower risk of worsening HF events.
Study context
- Population
- Patients with Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) or HF with Reduced EF (HFrEF)
- Participants
- 9,013 patients3 studies
- Comparison
- Digitalis glycosides vs placebo
- Digitalis glycosiden = 4,510
- Placebon = 4,503reference
- Outcome
- Composite of:
- Time to CV death
- First worsening HF event
Methodological detailsplacebo-controlled trials >1000 patients, fixed-effects model
- Placebo-controlled trials >1000 patients
- Fixed-effects model
Pooled result
As reported in the abstract
Hazard ratio
0.85
95% CI 0.80–0.90
P < 0.001
Events by group
Digitalis glycosidevs Placebo
HR 0.85 (95% CI 0.80–0.90); P < 0.001
Further pooled results
| Outcome | Digitalis glycoside | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| First worsening HF event | 26% | 33% | 0.75 (0.69–0.81) | P < 0.001 | |
| CV events | 27% | 27% | 0.99 (0.92–1.07) | P = 0.81 | |
| All-cause death | 32% | 33% | 0.97 (0.90–1.04) | P = 0.41 | |
| 0.512Hazard ratio (log scale) |
Heterogeneity by trial, digitalis type or background HF therapy
- No statistically significant heterogeneity by trial, type of digitalis glycoside or extent of background HF therapy
Original publication
Efficacy and Safety of Digitalis Glycosides in Heart Failure: A Meta-Analysis. JAMA. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →